SCHEMBL4152778

SCHEMBL4152778

O=C(NCCCc1cccnc1F)c1ccnc2[nH]c(-c3ccco3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.46
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CACNA1B Q00975 4/20 0.40
APBA1 Q02410 4/20 0.40
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
POLB P06746 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
HPGD P15428 3/20 0.36
CTDSP1 Q9GZU7 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
APOBEC3A P31941 1/20 0.36
HTT P42858 1/20 0.36
ESR2 Q92731 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
ADORA3 P0DMS8 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4145542 0.84 NAMPT (0.49) GSK3BMEN1KMT2ANPC1CACNA1B
SCHEMBL4157340 0.84 GSK3B (0.50) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4148273 0.84 PBK (0.52) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4153458 0.83 GSK3B (0.42) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4162798 0.82 GSK3B (0.48) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4152749 0.81 PKM (0.49) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4153424 0.80 NAMPT (0.55) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4153564 0.80 GSK3B (0.53) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4150171 0.80 GSK3B (0.47) GSK3BMEN1KMT2ANPC1RAB9A
SCHEMBL4961799 0.80 GSK3B (0.42) GSK3BMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885MEN1 3177/4885KMT2A 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.